Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07458425 · ClinicalTrials.gov registry record · NA
The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk
A NA study, sponsored by University of Illinois at Chicago.
- Recruiting
- Registry status
- NA
- Development phase
- 400
- Enrollment target
NCT07458425: Recruiting NA study, sponsored by University of Illinois at Chicago.
NCT07458425 is a NA study that is actively recruiting participants, run by University of Illinois at Chicago. The registered enrollment target is 400 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07458425, a NA study, is actively recruiting participants, sponsored by University of Illinois at Chicago.
- RECRUITING
- Registry status
- NA
- Development phase
- 400 participants
- Enrollment target
Study Summary
This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer over the next 3 years.
Primary Outcome
To evaluate participant reported outcomes before and after return of results (ROR) using the PROMIS test surveys
Interventions
- DIAGNOSTIC_TEST Artificial Intelligence (AI) test
- DIAGNOSTIC_TEST Research-use-only multimodal AI risk model
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 400 participants |
| Start Date | 2026-03-11 |
| Est. Completion | 2029-01 |
| Phase | NA |
What NCT07458425 shows while recruiting
NCT07458425 is an interventional study that assigns participants to a tested intervention. The registered 400 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 2 interventions - of which Artificial Intelligence (AI) test is the first listed.
NCT07458425 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07458425 about?
NCT07458425 is a clinical study titled "The SENTINL-1 Study: Evaluating Patient-Reported Outcomes of AI-Inferred Lung Cancer Risk". This is a two-cohort (screen naïve vs screen established), prospective, longitudinal, single-center clinical study design that will provide data to comprehensively evaluate patient-reported outcomes of Artificial Intelligence (AI) based prediction of an individual's risk of developing lung cancer ov...
What is the current status of trial NCT07458425?
This trial is currently recruiting. It is a NA study. The enrollment target is 400 participants. The study started on 2026-03-11. Estimated completion is 2029-01.
What interventions are being tested in trial NCT07458425?
The interventions under investigation include: Artificial Intelligence (AI) test (DIAGNOSTIC_TEST), Research-use-only multimodal AI risk model (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07458425?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07458425's enrollment target sits among peer trials
400 246th of 2000 higher than 1,734 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01665326 · 400 participants
Determination of CRIM Status and Longitudinal Follow-up of Individuals With Pompe Disease
- NCT02108054 · 400 participants · NA
Behavioral and Functional Task Development, Implementation, and Testing
- NCT02216500 · 400 participants · NA
Ketogenic Therapy Effects on Electrical and Metabolic Abnormalities in Epilepsy
- NCT02250352 · 400 participants
Core Biopsies for Establishing a Breast Tumor Tissue Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI